Future oncology最新文献_第9页

Hypofractionated radiotherapy for localized prostate cancer: the protocol for a prospective clinical trial. 低分割放疗治疗局限性前列腺癌：一项前瞻性临床试验方案。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-21 DOI: 10.1080/14796694.2025.2489340

Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang

{"title":"Hypofractionated radiotherapy for localized prostate cancer: the protocol for a prospective clinical trial.","authors":"Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang","doi":"10.1080/14796694.2025.2489340","DOIUrl":"10.1080/14796694.2025.2489340","url":null,"abstract":"Purpose: Compared to conventional fractionated radiotherapy (CFRT), which delivers lower doses over a longer period, moderate hypofractionated radiotherapy (HFRT) administers higher doses in a shorter period. Increasing evidence has demonstrated that the safety and efficacy of moderate HFRT in 20-28 fractions for localized PCa are equal to those of CFRT. However, the optimal and lowest fractions of moderate HFRT need to be explored for localized PCa. Therefore, this trial aims to investigate the safety outcomes of HFRT in 15 fractions for treating patients with localized PCa.Methods and analysis: This is a single-center, single-arm, open-label clinical trial. Patients with localized PCa will be enrolled to receive HFRT (54 Gy delivered in 15 daily fractions of 3.6 Gy). The primary outcome measures are the incidence of radiotherapy-related gastrointestinal (GI) and genitourinary (GU) symptoms and erectile dysfunction. Secondary outcome measures include biochemical progression-free survival (bPFS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and quality of life (QoL).Clinical trial registration: NCT06325774 (Clinicaltrials.gov).","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1483-1488"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plain language summary: how long do patients with metastatic castration-resistant prostate cancer (mCRPC) live when taking abiraterone or enzalutamide in the real world? 简单的语言总结：在现实世界中，转移性去势抵抗性前列腺癌（mCRPC）患者服用阿比特龙或恩杂鲁胺后能活多久？

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-25 DOI: 10.1080/14796694.2025.2485752

Daniel J George, Krishnan Ramaswamy, Hongbo Yang, Qing Liu, Adina Zhang, Alexandra Greatsinger, Jasmina Ivanova, Betty Thompson, Birol Emir, Agnes Hong, Stephen J Freedland

引用次数: 0

Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101. 神经内分泌肿瘤的α放射性配体疗法：RYZ101的现状和亮点。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1080/14796694.2025.2485650

Udhayvir S Grewal, Olumide B Gbolahan, Amol M Takalkar, Daniel M Halperin

{"title":"Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101.","authors":"Udhayvir S Grewal, Olumide B Gbolahan, Amol M Takalkar, Daniel M Halperin","doi":"10.1080/14796694.2025.2485650","DOIUrl":"10.1080/14796694.2025.2485650","url":null,"abstract":"The therapeutic landscape for neuroendocrine tumors (NETs) has rapidly evolved over the last three decades with the influx of a myriad of treatment options, such as somatostatin analogs (SSAs), targeted therapies, alkylating chemotherapies, and radioligand therapy (RLT). While the advent and regulatory approval of beta emitting RLT such as 177Lu-DOTATATE has offered a valuable therapeutic option for patients with NETs, there is still very significant room to tap the maximal therapeutic potential of RLT. Alpha RLT agents such as RYZ101 (225Ac-DOTATATE) offer a potential advantage over beta RLT due to more complex double-stranded DNA breaks and targeted cytotoxicity, as well as potential for minimizing off-target side-effects. Existing pre-clinical and clinical data suggest promising safety and efficacy of RYZ101 among patients with NETs. The ongoing phase 1b/3 trial ACTION-1 is poised to compare the safety and efficacy of RYZ101 against standard care therapies in advanced gastroenteropancreatic NETs (Ki67 ≤ 20%), after disease progression of prior 177Lu-SSA therapy. Yet, other alpha RLT agents are currently being investigated in both RLT-naïve as well-pre-treated patient populations. While long-term safety and efficacy data are awaited, alpha RLT agents such as RYZ101 offer a unique opportunity to enhance the therapeutic promise of RLT in NETs.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1357-1363"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). S2303：紫杉醇+ ramucirumab±nivolumab治疗胃和食管腺癌（PARAMUNE）的II/III期试验。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-28 DOI: 10.1080/14796694.2025.2485020

Anwaar Saeed, Sarah Colby, Paul Eliezer Oberstein, Dan G Duda, Robin Park, Rajiv Agarwal, Colmar Figueroa-Moseley, Riha Vaidya, Joseph M Unger, Katherine A Guthrie, Flavio G Rocha, Maheswari Senthil, Rachael A Safyan, Zev A Wainberg, Syma Iqbal, E Gabriela Chiorean, Philip A Philip

引用次数: 0

Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary. 帕博西尼和芳香酶抑制剂治疗激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌，已扩散到肺部或肝脏：简单的语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-30 DOI: 10.1080/14796694.2025.2481017

Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M Layman, Hope S Rugo

引用次数: 0

Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study. III期CASPIAN研究中广泛期小细胞肺癌患者自我报告的不良事件

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-05-07 DOI: 10.1080/14796694.2025.2491297

Mustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, Marina Chiara Garassino, Nenad Medic, Helen Mann, Priti Chugh, Tapashi Dalvi, Luis Paz-Ares

{"title":"Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.","authors":"Mustafa Özgüroğlu, Jonathan W Goldman, Yuanbin Chen, Marina Chiara Garassino, Nenad Medic, Helen Mann, Priti Chugh, Tapashi Dalvi, Luis Paz-Ares","doi":"10.1080/14796694.2025.2491297","DOIUrl":"10.1080/14796694.2025.2491297","url":null,"abstract":"Aim: In the phase III CASPIAN study, first-line durvalumab plus platinum-etoposide (EP) improved survival compared with EP in patients with extensive-stage small-cell lung cancer. We report an exploratory analysis of patient-reported adverse events (AEs).Methods: Of 537 patients randomized to durvalumab + EP or EP arms, 164 were asked to complete the Patient-Reported Outcomes version of the Common Terminology Criteria (PRO-CTCAE) for AEs at baseline, every 3 weeks (q3w) during EP, then q4w until disease progression, then post-progression on day 28, 2 months, and q8w until second progression/death. Presence/absence, frequency, or severity of 11 selected AEs were examined during the first 24 weeks of treatment, alongside interference with usual/daily activities for five AEs.Results and conclusions: A minority of patients reported the examined AEs before starting treatment, from 3-5% who reported hand-foot syndrome, up to 34-41% for dry mouth. AE rates were generally comparable with baseline and the patterns of AEs reported by patients over time were similar in both treatment arms. Most patients indicated that reported AEs occurred rarely/occasionally and were mild/moderate in severity. These PRO-CTCAE data complement the clinician-reported AEs and give insight into patients' experience of treatment.Clinical trial registration: www.clinicaltrials.gov identifier is NCT03043872.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1511-1523"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites. 神经营养酪氨酸受体激酶阳性实体瘤部位的流行病学系统文献综述。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-03-28 DOI: 10.1080/14796694.2025.2481022

Reginald Villacorta, Shannon Gallagher-Colombo, Armin Lahiji, Sky Myers, Jonathon Briggs, Angaja Phalguni

{"title":"Systematic literature review of the epidemiology of neurotrophic tyrosine receptor kinase positive solid tumor sites.","authors":"Reginald Villacorta, Shannon Gallagher-Colombo, Armin Lahiji, Sky Myers, Jonathon Briggs, Angaja Phalguni","doi":"10.1080/14796694.2025.2481022","DOIUrl":"10.1080/14796694.2025.2481022","url":null,"abstract":"Aims: This study aimed to expand on existing systematic literature reviews (SLRs) by assessing the prevalence of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive mutations across solid tumors in adult U.S populations. It further evaluated incidence, testing, treatment, mortality, and progression rates by tumor type, extending evidence through 2023.Materials & methods: A SLR was conducted following Cochrane and PRISMA guidelines, with searches across Ovid Embase, Ovid MEDLINE, and Cochrane Library databases for studies published from 2013 to August 2023. Eligibility criteria included studies on NTRK fusion-positive tumors in patients aged ≥12 years. Data were extracted and assessed using the Newcastle-Ottawa Scale and JBI checklist.Results: This SLR identified 160 studies, reporting NTRK fusion prevalence ranging from 0.03% to 0.70% across solid tumors. TRK inhibitors, particularly larotrectinib and entrectinib, were commonly used treatments. Prevalence varied significantly by cancer type, being higher in rarer cancers, such as papillary thyroid carcinoma (up to 21.4%).Conclusions: NTRK fusions are rare, with wide prevalence variability among cancer types. The findings highlight the need for standardized diagnostic methods and larger real-world studies to improve prevalence estimates and assess the impact of NTRK fusions on outcomes, ultimately aiding in the optimization of targeted treatments for affected patients.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1403-1415"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. ELAINE 3: lasofoxifene联合abemaciclib治疗ER+/HER2-， esr1突变的转移性乳腺癌的3期研究

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-13 DOI: 10.1080/14796694.2025.2481825

Matthew P Goetz, Seth A Wander, Thomas Bachelot, Alexandre de Nonneville, Einav Nili Gal-Yam, Sarah L Sammons, Sherry Shen, Chris Twelves, Gina Boruta, David J Portman, Senthil Damodaran

{"title":"ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer.","authors":"Matthew P Goetz, Seth A Wander, Thomas Bachelot, Alexandre de Nonneville, Einav Nili Gal-Yam, Sarah L Sammons, Sherry Shen, Chris Twelves, Gina Boruta, David J Portman, Senthil Damodaran","doi":"10.1080/14796694.2025.2481825","DOIUrl":"https://doi.org/10.1080/14796694.2025.2481825","url":null,"abstract":"Endocrine therapy (ET) is recommended for patients with estrogen receptor-positive (ER+) metastatic breast cancer (mBC), but most patients will develop treatment resistance, often due to mutations in the ER-α-coding gene, ESR1. Therapeutic options are limited for endocrine-resistant mBC, particularly following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Lasofoxifene had anti-tumor activity in two separate phase 2, open-label studies (ELAINE 1 and 2) when given as monotherapy or combined with abemaciclib. The phase 3, randomized ELAINE 3 trial will evaluate the efficacy and safety of lasofoxifene/abemaciclib versus fulvestrant/abemaciclib for locally advanced or metastatic, ER+/HER2- breast cancer with an ESR1 mutation that progressed after ET-CDK4/6i treatment. Enrollment is planned for up to 500 patients to evaluate progression-free survival as the primary endpoint.Clinical trial registration: www.clinicaltrials.gov identifier is NCT05696626.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 11","pages":"1317-1324"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Order of treatment with ALK inhibitors and its effect on people with lung cancer in the real world: a plain language summary. ALK抑制剂的治疗顺序及其在现实世界中对肺癌患者的影响：简单的语言总结。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-24 DOI: 10.1080/14796694.2025.2489319

Jessica R Bauman, Geoffrey Liu, Isabel Preeshagul, Barbara Melosky, Devin Abrahami, Benjamin Li, Despina Thomaidou, Stan Krulewicz, Martin Rupp

引用次数: 0

Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry. 局部和弥漫性腱鞘巨细胞瘤：来自患者观察登记的真实结果。

IF 3 4区医学

Future oncology Pub Date : 2025-05-01 Epub Date: 2025-04-08 DOI: 10.1080/14796694.2025.2488635

Sydney Stern, Patrick F McKenzie, Nicholas Bernthal, Shannon O'Neill, Emanuela Palmerini, R Lor Randall, William Tap, Thomas Scharschmidt, Sara Rothschild

{"title":"Localized and diffuse tenosynovial giant cell tumor: real-world results from a patient observational registry.","authors":"Sydney Stern, Patrick F McKenzie, Nicholas Bernthal, Shannon O'Neill, Emanuela Palmerini, R Lor Randall, William Tap, Thomas Scharschmidt, Sara Rothschild","doi":"10.1080/14796694.2025.2488635","DOIUrl":"10.1080/14796694.2025.2488635","url":null,"abstract":"Background: Tenosynovial Giant Cell Tumor (TGCT) is a rare, locally aggressive neoplasm that adversely impact patients' physical function and quality of life (QoL). This cross-sectional analysis leverages real-world data from the TGCT Support Patient Registry to elucidate the patient experience with TGCT and the disease burden across healthcare systems.Research design and methods: A total of 497 patients from 32 countries, 71.4% (n = 355) with diffuse-TGCT (D-TGCT), 18.9% (n = 94) with localized TGCT (L-TGCT), and 9.7% (n = 28) with unspecified TGCT were included in this cross-sectional analysis of the TGCT Support Registry.Results: A majority of patients (61.2%, n = 304) were diagnosed by orthopedic/sports medicine surgeons, half (n = 248) were misdiagnosed prior to their TGCT diagnosis, and 32% (n = 278) of patients were diagnosed > 24 months following symptom onset. 79.1% (n = 393) of all patients had ≥ 1 resection and 63% of those patients reported ≥ 1 recurrence. Of those patients that had recurrence following resection, 59% had ≥ 2 recurrences. 23% of patients (n = 115) changed occupations or prematurely retired due to TGCT and the proportion of patients increased with > 2 surgeries.Conclusion: Greater awareness of TGCT among HCPs is needed to facilitate diagnosis and referral to multidisciplinary teams is warranted to reduce recurrence rates, number of surgical interventions, and improve QoL.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1501-1510"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0